Clinical Study Now Recruiting: Hair Loss Treatment for Skin of Color with New FoLix Laser Therapy
- Jaime P. Morales
- Jun 19
- 3 min read
Updated: Sep 8
Currently Recruiting
Are You Struggling with Hair Thinning? This New Clinical Trial May Help, Especially for Those with Darker Skin Tones
If you’re between 21 and 55, have moderate hair loss, and identify as having a Fitzpatrick Skin Type V or VI (typically deeper skin tones), you may be eligible to join a groundbreaking clinical study testing a new non-invasive laser treatment for hair regrowth.
Here’s everything you need to know.
What’s the Hair Loss Treatment Study About?
Researchers are testing an FDA-cleared laser device called FoLix, which has been approved for hair loss treatment in lighter skin types (I-IV). Now, they’re looking to see how effective it is for darker skin tones (types V & VI).
This is an exciting opportunity for people of color to access advanced, safe, and potentially effective hair restoration technology that hasn’t been thoroughly studied in this group, until now.
Who Can Join the Study?
You may qualify if:
You are 21 to 55 years old
Have a Fitzpatrick Skin Type V or VI
Experience mild to moderate hair thinning
Women: Ludwig scale I–II
Have been noticing hair loss for more than 6 months but less than 5 years
Are in generally good health
Can commit to four treatment visits over a few months
Are willing to keep the same hairstyle and use non-medicated shampoo during the study
Who Should Not Apply to the Hair Loss Treatment Study?
You are not eligible if you:
Have skin types I–IV
Have conditions like alopecia areata, scalp diseases, or scarring hair loss
Are pregnant, breastfeeding, or planning to become pregnant soon
Have had recent hair loss treatments or transplants
Are using hair growth products like minoxidil or finasteride
Smoke more than 20 cigarettes/day
Have serious health conditions that could interfere with participation
What’s Involved in the Study?
Receive 4 FoLix laser treatments spaced 4 weeks apart
Have scalp images taken with a high-res macro camera to track progress
Results assessed by three independent, blinded reviewers
Use of gentle shampoo/conditioner during the study period
No cost to participate!
Why This Study Matters
Hair loss can affect confidence, self-esteem, and identity, especially for people with deeper skin tones who often face limited treatment options. This study is part of a push toward inclusive and effective hair loss solutions that reflect the needs of diverse populations.
Your participation could help expand access to cutting-edge therapies for others with similar skin and hair types.
Interested? Here’s How to Apply
Contact: Keren Hayut
Phone: +972-506905252
Email: keren.hayut@lumenis.com
Blog Disclaimer
This blog is an independent platform created to share publicly available information about ongoing research studies, primarily sourced from the official NIH (National Institutes of Health) website and other publicly accessible databases. Our goal is to hold space for individuals to explore research opportunities that may align with their interests or health profiles.
We do not work directly with the research teams or institutions conducting these studies, nor are we involved in participant selection, communication, or study oversight. All decisions regarding participation are determined solely by the research teams based on their specific study requirements and eligibility criteria.
We do not receive funding or compensation from research programs or from individuals who choose to participate. This platform is informational only and is not intended to replace professional medical advice or the official study pages.
If you choose to provide your email address, it will be used solely to share information about current or future research studies that may be of interest. Your email will never be sold, shared, or provided to research teams or third partieswithout your explicit permission.
For detailed information or to apply to a study, please contact the listed study coordinators directly through the links provided.
Comments